SCHEMBL6249698

SCHEMBL6249698

COc1ccc(C(F)(F)F)cc1N(C(N)=O)c1ccc(C)cc1F

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
CETP P11597 1/20 0.41
MAPK1 P28482 1/20 0.39
HPGD P15428 2/20 0.38
SCN8A Q9UQD0 1/20 0.38
SCN10A Q9Y5Y9 1/20 0.38
RAB9A P51151 1/20 0.37
KDM4E B2RXH2 2/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CTSA P10619 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
ERAP1 Q9NZ08 2/20 0.36
CSF1R P07333 1/20 0.36
RORC P51449 1/20 0.36
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6258541 0.89 SCN8A (0.40) MAPTSCN8ASCN10AKDM4EHCRTR1
SCHEMBL14760908 0.86 MAPT (0.41) MAPTCETPHPGDSCN8ASCN10A
SCHEMBL13388545 0.84 MAPT (0.43) MAPTCETPMAPK1HPGDSCN8A
SCHEMBL6959867 0.81 MAPT (0.37) MAPTHCRTR1HCRTR2ERAP1
SCHEMBL6364181 0.80 POLQ (0.41) MAPTSCN8ASCN10AHCRTR1HCRTR2
SCHEMBL8171575 0.78 HPGD (0.45) HPGDRAB9AHCRTR1HCRTR2KMT2A
SCHEMBL13388895 0.77 MAPT (0.43) MAPTHPGDKDM4EHCRTR1HCRTR2
SCHEMBL5596997 0.75 MAPT (0.43) MAPTHPGDRAB9AKDM4EHCRTR1
SCHEMBL6114202 0.75 MAPT (0.43) MAPTMAPK1HPGDSCN8ASCN10A
SCHEMBL27151678 0.74 MAPT (0.36) MAPTHPGDKDM4EHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER HEALTHERCARE LLC (US) 2012-10-25 US claimed
WO-2005032551-A1 TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE SCIOS INC. (US) 2005-04-14 WO disclosed
EP-1042305-A4 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER AG (US) 2003-05-14 EP disclosed
EP-1042305-A1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS Bayer Corporation (US) 2000-10-11 EP disclosed
WO-1999032463-A1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER CORPORATION (US) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS MAP2K2, MAPK1, MAP2K1 MAPT 618/4885CETP 3135/4885MAPK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.